| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 83270-0451-05 | 83270-0451 | ETOPOSIDE | ETOPOSIDE | 50.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Oral | May 29, 2026 | In Use | |
| 83831-0183-04 | 83831-0183 | Bendamustine hydrochloride | BENDAMUSTINE HYDROCHLORIDE | 100.0 mg/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | May 29, 2026 | In Use | |
| 70518-3818-01 | 70518-3818 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 26, 2026 | In Use | ||
| 70518-1704-02 | 70518-1704 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 26, 2026 | In Use | |
| 72162-2647-02 | 72162-2647 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 21, 2026 | In Use | |
| 72162-2647-01 | 72162-2647 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 21, 2026 | In Use | |
| 55154-2582-00 | 55154-2582 | PREDNISONE | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 20, 2026 | In Use | |
| 46708-0311-35 | 46708-0311 | Bosutinib | Bosutinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 62332-0311-35 | 62332-0311 | Bosutinib | Bosutinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 46708-0312-30 | 46708-0312 | Bosutinib | Bosutinib | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 62332-0312-30 | 62332-0312 | Bosutinib | Bosutinib | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 69238-2811-02 | 69238-2811 | Etoposide | VePesid | 50.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Oral | May 15, 2026 | In Use | |
| 70518-4038-09 | 70518-4038 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 13, 2026 | In Use | |
| 70518-4660-00 | 70518-4660 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 13, 2026 | In Use | |
| 70771-1966-01 | 70771-1966 | Hydrocortisone sodium succinate | Hydrocortisone sodium succinate | 100.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | May 9, 2026 | In Use | |
| 70710-1907-01 | 70710-1907 | Hydrocortisone sodium succinate | Hydrocortisone sodium succinate | 100.0 mg/2mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | May 9, 2026 | In Use | |
| 68071-3999-03 | 68071-3999 | Anastrozole Tablets | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 7, 2026 | In Use | ||
| 85766-0206-05 | 85766-0206 | Triamcinolone Acetonide | Triamcinolone Acetonide | 200.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | May 7, 2026 | In Use | |
| 72162-2634-02 | 72162-2634 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 6, 2026 | In Use | |
| 72162-2642-02 | 72162-2642 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | May 6, 2026 | In Use | |
| 72162-2640-02 | 72162-2640 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 6, 2026 | In Use | |
| 50268-0032-12 | 50268-0032 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | May 4, 2026 | In Use | |
| 50881-0011-08 | 50881-0011 | Ruxolitinib | JAKAFI XR | 11.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 50881-0022-08 | 50881-0022 | Ruxolitinib | JAKAFI XR | 22.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use | |
| 50881-0044-08 | 50881-0044 | Ruxolitinib | JAKAFI XR | 44.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | May 1, 2026 | In Use |
Found 12393 results — Export these results
Home